<code id='F8DC5F31F9'></code><style id='F8DC5F31F9'></style>
    • <acronym id='F8DC5F31F9'></acronym>
      <center id='F8DC5F31F9'><center id='F8DC5F31F9'><tfoot id='F8DC5F31F9'></tfoot></center><abbr id='F8DC5F31F9'><dir id='F8DC5F31F9'><tfoot id='F8DC5F31F9'></tfoot><noframes id='F8DC5F31F9'>

    • <optgroup id='F8DC5F31F9'><strike id='F8DC5F31F9'><sup id='F8DC5F31F9'></sup></strike><code id='F8DC5F31F9'></code></optgroup>
        1. <b id='F8DC5F31F9'><label id='F8DC5F31F9'><select id='F8DC5F31F9'><dt id='F8DC5F31F9'><span id='F8DC5F31F9'></span></dt></select></label></b><u id='F8DC5F31F9'></u>
          <i id='F8DC5F31F9'><strike id='F8DC5F31F9'><tt id='F8DC5F31F9'><pre id='F8DC5F31F9'></pre></tt></strike></i>

          focus

          focus

          author:explore    Page View:45
          Christine Kao/STAT

          The Food and Drug Administration on Friday approved the world’s first medicine based on CRISPR gene-editing technology, a groundbreaking treatment for sickle cell disease that delivers a potential cure for people born with the chronic and life-shortening blood disorder.

          The new medicine, called Casgevy, is made by Vertex Pharmaceuticals and CRISPR Therapeutics. Its authorization is a scientific triumph for the technology that can efficiently and precisely repair DNA mutations — ushering in a new era of genetic medicines for inherited diseases.

          advertisement

          In a clinical trial, Casgevy was shown to eliminate recurrent episodes of debilitating pain caused by sickle cell, which afflicts approximately 100,000 people in the U.S., a vast majority of whom are Black. The therapy, whose scientific name is exa-cel, is described as a potential cure because the genetic fix enabled by CRISPR is designed to last a lifetime, although confirmation will require years of follow-up.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          Bright Health sells Medicare Advantage business to Molina
          Bright Health sells Medicare Advantage business to Molina

          BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

          read more
          Princess Kate attends Wimbledon with Roger Federer: See the photos
          Princess Kate attends Wimbledon with Roger Federer: See the photos

          1:00RogerFedererwithHerRoyalHighness,Catherine,PrincessofWalesintheCentreCourt'sRoyalBoxduringtheWim

          read more
          Jerome Adams on the need for new antivirals for Covid
          Jerome Adams on the need for new antivirals for Covid

          PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

          read more

          HCA says smaller share of spending going to labor

          AdobeThechiefexecutiveofthecountry’sbiggesthospitalchainsaidThursdaythatlaborcostsarenowlowerasaperc